Responses
Abstracts Accepted for Publication
Spondyloarthritis - treatment
AB0736 Secukinumab Significantly Improves Physical Function, Quality of Life, and Work Productivity Through 52 Weeks in Subjects with Active Ankylosing Spondylitis in the Phase 3 Measure 2 Study
Compose a Response to This Article
Other responses
No responses have been published for this article.